PIWA
REGN icon

Prevail Innovative Wealth Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Prevail Innovative Wealth Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-7,628
Closed -$4.29M – 227
2025
Q3 		$4.29M Buy
+7,628
New +$4.31M 0.83% 40

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Prevail Innovative Wealth Advisors's REGN Position: Q4 2025 in Review

Prevail Innovative Wealth Advisors sold out of Regeneron Pharmaceuticals (REGN) in Q4 2025, closing a stake of 7,628 shares — an estimated $4.29M sold.

Prevail Innovative Wealth Advisors first reported a position in REGN in Q3 2025 and held it in 1 quarter. The position peaked at $4.29M in Q3 2025. 1,386 funds tracked by Wall St. Rank hold REGN as of Q4 2025.

  • Prevail Innovative Wealth Advisors reported no remaining Regeneron Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Prevail Innovative Wealth Advisors sold 7,628 Regeneron Pharmaceuticals shares in Q4 2025, an estimated $4.29M.
  • Prevail Innovative Wealth Advisors first reported a position in Regeneron Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • Prevail Innovative Wealth Advisors's Regeneron Pharmaceuticals position peaked at $4.29M in Q3 2025.
  • 1,386 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2025.

Based on Prevail Innovative Wealth Advisors's 13F filing for Q4 2025, filed 6 Feb 2026.